SILO

Silo Pharma, Inc. (SILO) - Q3 2024 10-Q Summary

Business Context and Reporting Period

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on novel therapeutics for under-served conditions, including PTSD, fibromyalgia, Alzheimer's disease, and multiple sclerosis. The company operates as a smaller reporting company and is incorporated in Nevada. This summary covers the quarterly period ended September 30, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Remained flat at $54,076 for the nine months ended September 30, 2024, compared to the same period in 2023. Revenue is derived entirely from deferred license fees recognized over a 15-year term from an agreement with Aikido Pharma Inc.
• Operating Expenses: Total operating expenses increased to $2.94 million for the nine months ended September 30, 2024, from $2.74 million in the prior year.
  • R&D: Increased significantly by 154.4% to $1.29 million (from $508k) due to costs associated with Investigator-sponsored Study Agreements.
  • Compensation: Decreased by 28.0% to $511k, primarily due to a $200,000 bonus paid in 2023 that was not repeated in 2024.
  • Professional Fees: Decreased by 29.3% to $900k, driven by lower legal and consulting fees.
• Other Income: Net other income increased to $230k (from $112k) largely due to the absence of a $166k penalty for early termination of a certificate of deposit incurred in 2023.
• Liquidity: Cash and cash equivalents increased to $4.86 million from $3.52 million at year-end 2023, bolstered by equity financing. Short-term debt investments decreased to $3.15 million from $4.14 million as the company sold investments to fund operations.

Guidance, Outlook, and Risks

• Capital Raising: The company completed two registered direct offerings in 2024. In June, it raised net proceeds of $1.67 million. In July, it raised net proceeds of $1.74 million. Proceeds are designated for working capital and general corporate purposes.
• Strategic Agreements: In July 2024, the company entered into an exclusive license agreement with Columbia University for the development of SPC-15 (PTSD/anxiety). The agreement involves an initial fee of $50,000 and reimbursement of past patent expenses totaling $197,400, recorded as intangible assets.
• Liquidity Outlook: Management believes current cash and short-term investments are sufficient to meet obligations for at least the next twelve months. Working capital is positive at $7.2 million.
• Risks:
  • Going Concern: While working capital is positive, the company has an accumulated deficit of $13.5 million and relies on future financing or revenue generation.
  • Internal Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2024, citing material weaknesses including a lack of segregation of duties and inadequate system controls.
  • Concentration: 100% of revenue comes from a single licensee (Aikido Pharma). 100% of vendor license agreements are with two licensors.

Investor Verification Checklist

• Runway Validation: Verify if the $8 million in liquid assets (cash + short-term investments) is sufficient to cover the projected $3.1 million in future sponsored study commitments plus ongoing operating losses.
• Internal Control Remediation: Review the company's plan to address the material weaknesses in internal controls over financial reporting identified in Item 4.
• Revenue Sustainability: Confirm the terms of the Aikido Pharma license agreement and the likelihood of future revenue beyond the current deferred recognition schedule.
• Dilution Impact: Assess the impact of the 2.2 million outstanding warrants (weighted average exercise price $4.55) on future share count and potential dilution.
• Columbia License Milestones: Monitor progress on the SPC-15 program under the new Columbia University agreement to ensure milestone payments are not triggered prematurely.